{"gene":"AXIN2","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":2002,"finding":"AXIN2 is a direct transcriptional target of the Wnt/β-catenin pathway, induced through TCF/LEF binding sites in its promoter and first intron; mutation or deletion of these sites abolished β-catenin-mediated induction, establishing a negative feedback loop where AXIN2 promotes β-catenin phosphorylation and degradation.","method":"Reporter constructs with promoter/intron fragments, EMSA with Tcf/LEF sites, transgenic embryo expression, endogenous mRNA/protein induction assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods (EMSA, reporter assays, mutagenesis, transgenic mice) in two independent papers","pmids":["11809808","11809809"],"is_preprint":false},{"year":2002,"finding":"AXIN2/conductin functions as a negative regulator of Wnt signaling by inducing β-catenin degradation through functional interaction with the tumor suppressor APC and the serine/threonine kinase GSK3β.","method":"Co-functional studies in tumor cell lines with dominant-negative TCF, Wnt-1 and Dishevelled activation, western blot for β-catenin","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — replicated across multiple studies, consistent with established destruction complex mechanism","pmids":["11809809"],"is_preprint":false},{"year":2006,"finding":"Canonical Wnt signaling stabilizes the Snail1 zinc-finger transcription factor through an Axin2-GSK3β axis: Axin2 acts as a nucleocytoplasmic chaperone for GSK3β, relocating it from the nucleus, thereby reducing GSK3β-mediated Snail1 phosphorylation and degradation to drive EMT and breast cancer invasion.","method":"Knockdown/overexpression in breast cancer cells, nuclear/cytoplasmic fractionation, Snail1 protein turnover assays, invasion assays","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 — multiple mechanistic readouts (GSK3β localization, Snail1 stability, invasion) in a single high-impact study","pmids":["17072303"],"is_preprint":false},{"year":2005,"finding":"Axin and Axin2 proteins are functionally equivalent in vivo; knockin of Axin2 cDNA under the Axin locus rescues Axin-null lethality, demonstrating that their different phenotypes arise from distinct expression patterns rather than different biochemical activities.","method":"Knockin mouse generation (Axin locus replaced with Axin or Axin2 cDNA), viability and fertility assessment of homozygotes","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 — in vivo genetic equivalence demonstrated by knockin rescue","pmids":["15899843"],"is_preprint":false},{"year":2005,"finding":"Axin2 is expressed at osteogenic fronts and periosteum of developing sutures; targeted disruption of Axin2 causes craniosynostosis through enhanced β-catenin signaling, promoting osteoprogenitor expansion and accelerated osteoblast differentiation.","method":"Axin2-null mouse analysis, in vivo/in vitro osteoblast proliferation and differentiation assays, β-catenin signaling readouts","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 — KO mouse with defined cellular phenotype and pathway placement","pmids":["15790973"],"is_preprint":false},{"year":2006,"finding":"In osteoprogenitors, β-catenin acts as a transcriptional co-activator driving cyclin D1 expression to promote proliferation; upon differentiation, β-catenin switches to an adhesion role via adherens junctions. Haploid deficiency of β-catenin rescues Axin2-null craniosynostosis, confirming that Axin2 suppresses both proliferative and adhesive β-catenin functions.","method":"Genetic rescue (Axin2-null × β-catenin heterozygous mice), BMP signaling assays, adherens junction analysis","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 — epistasis demonstrated by double-mutant rescue with defined phenotypic readout","pmids":["17113065"],"is_preprint":false},{"year":2010,"finding":"Conductin/Axin2 localizes at centrosomes by binding to the centriole-associated protein C-Nap1, and promotes phosphorylation of β-catenin (Ser33/37, Thr41) at centrosomes; loss of conductin causes premature centrosome separation dependent on β-catenin but independent of β-catenin-mediated transcription.","method":"Co-immunoprecipitation (conductin–C-Nap1), knockdown/knockout, centrosome imaging, phospho-β-catenin mutant rescue, transcription inhibitor controls","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 — reciprocal binding demonstrated, phenotype rescued by phospho-mimetic mutant, transcription-independent mechanism confirmed","pmids":["20300119"],"is_preprint":false},{"year":2011,"finding":"Axin2 is required for normal kinetics of oligodendrocyte progenitor differentiation and remyelination; tankyrase inhibitor XAV939 stabilizes Axin2 levels in OLPs and accelerates their differentiation after hypoxic/demyelinating injury.","method":"Axin2 KO mice, XAV939 pharmacological stabilization, remyelination assays in brain and spinal cord injury models","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 — KO mice with defined cellular phenotype plus pharmacological rescue with mechanism","pmids":["21706018"],"is_preprint":false},{"year":2012,"finding":"Conductin/Axin2 levels peak at G2/M and are degraded by the APC/C cofactor CDC20, allowing maximal Wnt/β-catenin target gene activity at G1/S; CDC20-resistant conductin inhibits Wnt signaling and colony formation of colorectal cancer cells.","method":"Cell cycle synchronization, CDC20 knockdown, CDC20-resistant conductin overexpression, colony formation assays, β-catenin phosphorylation analysis","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 — CDC20 identified as the E3 adaptor for conductin degradation with functional consequence on Wnt signaling","pmids":["22322943"],"is_preprint":false},{"year":2012,"finding":"In colorectal cancer cells with activated Wnt signaling, Axin2 promotes oncogenic behavior by stabilizing Snail1 activity and driving EMT; silencing Axin2 decreases Snail1, reverses EMT, and inhibits invasion and metastasis.","method":"Axin2 siRNA knockdown in CRC cells, Snail1 activity assays, EMT markers, in vivo metastasis models, transcriptome analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods in vitro and in vivo, mechanistic pathway defined","pmids":["22745173"],"is_preprint":false},{"year":2013,"finding":"p53 regulates nuclear GSK3β levels via miR-34-mediated suppression of Axin2; Axin2 acts as a cytoplasmic anchor retaining GSK3β outside the nucleus, and its suppression increases nuclear GSK3β abundance, leading to decreased Snail expression.","method":"miR-34a overexpression, Axin2 UTR-reporter assays, nuclear/cytoplasmic GSK3β fractionation, Snail protein level measurement, miR-sponge construct","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2–3 — single lab, mechanistic chain established through UTR reporter and fractionation but limited by single-method validation of each step","pmids":["23624843"],"is_preprint":false},{"year":2014,"finding":"Conductin/Axin2 shows reduced binding to Dvl2 compared to Axin1, making β-catenin degradation by conductin relatively insensitive to Dvl-mediated inhibition; this insensitivity to upstream Wnt pathway components is a key feature of conductin's role as a negative-feedback regulator.","method":"Domain-swap constructs, Co-IP of conductin/axin with Dvl2, β-catenin degradation assays with Dvl2 co-expression","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP and functional assays in single lab establishing biochemical mechanism","pmids":["25380820"],"is_preprint":false},{"year":2017,"finding":"AXIN2 is the rate-limiting scaffold for formation of tankyrase-inhibitor-induced degradasomes (β-catenin destruction complex assemblies); depletion of AXIN2 (but not AXIN1) substantially impairs degradasome formation and β-catenin degradation in colorectal cancer cells.","method":"siRNA knockdown of AXIN1 vs AXIN2 in SW480 cells treated with tankyrase inhibitor G007-LK, immunofluorescence of degradasomes, β-catenin levels","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — clean genetic dissection of AXIN1 vs AXIN2 roles with defined phenotypic readout","pmids":["28107521"],"is_preprint":false},{"year":2019,"finding":"Conductin/Axin2 contains an aggregation site (aggregon) in its RGS domain that prevents its polymerization and limits its activity; mutations masking this aggregon enhance conductin polymerization and β-catenin degradation. A peptide targeting this aggregon induces conductin polymerization, enhancing β-catenin degradation and suppressing colorectal cancer growth.","method":"Domain-swapping between axin and conductin, point mutations of aggregon, in vitro polymerization assays, β-catenin degradation assays, colorectal cancer cell growth assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 — biochemical reconstitution of polymerization, mutagenesis validation, functional cancer cell assays","pmids":["31534175"],"is_preprint":false},{"year":2022,"finding":"Gαi2, a subunit of trimeric G-proteins, induces conductin/Axin2 condensation by targeting the polymerization-inhibiting aggregon in its RGS domain, promoting conductin-mediated β-catenin degradation and Wnt pathway suppression; the FDA-approved drug guanabenz activates Gαi2 to inhibit Wnt signaling via conductin condensation.","method":"Gαi2 co-expression/knockdown, condensate imaging, β-catenin degradation assays, colorectal cancer xenograft models, guanabenz treatment","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — mechanistic pathway (Gαi2→aggregon→condensation→β-catenin degradation) validated with multiple orthogonal methods in vitro and in vivo","pmids":["35115535"],"is_preprint":false},{"year":2009,"finding":"Axin2 regulates bone remodeling by controlling β-catenin-BMP2/4-Osx signaling in osteoblasts; Axin2 KO mice show increased trabecular bone mass and osteoblast differentiation, with elevated BMP2/4 expression and phospho-Smad1/5, and BMP2/4 deletion blocks β-catenin-induced osteoblast marker expression.","method":"Axin2-null mice, BMS cell isolation, β-catenin conditional deletion, BIO chemical inhibitor, Bmp2/4-flox adenoviral Cre deletion, siRNA knockdown of Osx","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic epistasis experiments establishing Axin2→β-catenin→BMP2/4→Osx pathway","pmids":["19737815"],"is_preprint":false},{"year":2013,"finding":"Runx2 represses Axin2 transcription through binding to multiple Axin2 promoter regions in a manner dependent on Hdac3; haploinsufficiency of Runx2 in Axin2-null mice rescues craniosynostosis, placing Runx2-Hdac3 upstream of Axin2 in intramembranous bone development.","method":"ChIP (Runx2 at Axin2 promoter), Hdac3 co-repressor assay, Axin2-null × Runx2-heterozygous double mutant mouse rescue","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — ChIP plus double-mutant genetic rescue defining transcriptional regulatory pathway","pmids":["23300083"],"is_preprint":false},{"year":2003,"finding":"TCF-4 interacts with the transcriptional co-repressor CtBP1 via its C-terminus; CtBP1 represses TCF/β-catenin-dependent transcription including endogenous Axin2/conductin expression, and this repression is relieved by histone deacetylase inhibition (trichostatin A), indicating HDAC-dependent co-repressor activity.","method":"Co-IP of TCF-4 and CtBP1, synthetic promoter reporter assay, endogenous Axin2 mRNA measurement, trichostatin A treatment","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2–3 — Co-IP plus reporter assay in single study, mechanism partially defined","pmids":["12711682"],"is_preprint":false},{"year":2011,"finding":"In Axin2(canp) mutant mice carrying a V26D substitution in an N-terminal motif, Axin2 protein is more stable than wild type, leading to decreased Wnt signaling in most tissues but paradoxical increased Wnt activity in the late primitive streak; tankyrase inhibitor-induced Axin stabilization in wild-type embryos recapitulates this tissue-specific paradox.","method":"ENU-induced V26D knockin mice, Wnt reporter readouts in different tissues, tankyrase inhibitor treatment of wild-type embryos","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 — mutagenesis and pharmacological validation, tissue-specific mechanistic insight from single lab","pmids":["21555575"],"is_preprint":false},{"year":2017,"finding":"Rap1b acts downstream of Axin2 in skeletal progenitor cells; Axin2 regulates Rap1b through modulation of canonical BMP signaling, and Rap1b-mediated inhibition of MAPK antagonizes FGF signaling to repress osteoblast differentiation while promoting chondrogenesis.","method":"Axin2 and Rap1b knockout mice, genetic epistasis, BMP/FGF/MAPK signaling assays, cell fate analysis","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 2 — genetic pathway placement with multiple signaling readouts; single lab","pmids":["28520221"],"is_preprint":false},{"year":2023,"finding":"Axin2 suppresses p53 signaling at the post-transcriptional level to maintain neural progenitor cell fitness; in genetic mosaic conditions, Axin2-deficient cells are eliminated by p53-dependent apoptosis (cell competition), and combined Axin2/p53 loss increases cortical area and thickness.","method":"Mosaic Axin2 knockout vs. homogeneous knockout mice, genetic double mutant (Axin2 + Trp53), cortical area/thickness measurement, apoptosis assays","journal":"Developmental cell","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis via double knockout with defined developmental phenotype; single lab","pmids":["37054704"],"is_preprint":false},{"year":2023,"finding":"ALKBH5, an m6A RNA eraser, binds and demethylates AXIN2 mRNA, causing its dissociation from the m6A reader IGF2BP1 and consequent degradation, thereby hyperactivating Wnt/β-catenin signaling and inducing DKK1-mediated immunosuppression in colorectal cancer.","method":"MeRIP-seq, RNA IP, siRNA knockdown, humanized mouse models, allografts, Alkbh5 knockin mice","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 — m6A modification site on AXIN2 mRNA identified by MeRIP-seq, mechanism validated in multiple in vivo models","pmids":["37169182"],"is_preprint":false},{"year":2023,"finding":"In ASD neurons, Axin2 interacts with the glycolytic enzyme ENO1; the tankyrase inhibitor XAV939 blocks Axin2/ENO1 interaction and stabilizes Axin2, shifting the glycolysis/oxidative phosphorylation balance and rescuing synaptic maturation and social behavior deficits.","method":"Co-IP of Axin2 and ENO1 in ASD mouse/human neurons, XAV939 treatment, glycolysis assays, behavioral rescue in Shank3-/- and VPA-treated mice","journal":"EMBO molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2–3 — novel Axin2–ENO1 interaction identified by Co-IP with functional rescue; single lab","pmids":["37078424"],"is_preprint":false},{"year":2005,"finding":"E2F1 upregulates Axin2 by two independent mechanisms: direct transcriptional activation of a specific 5' UTR variant via canonical E2F binding sites, and stabilization of Axin2 mRNA, establishing Axin2 as a point of cross-talk between the Rb/E2F and Wnt/β-catenin pathways.","method":"Reporter assays with E2F binding site mutations, mRNA stability assays, E2F1 overexpression","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2–3 — two mechanisms identified but single lab with partial validation","pmids":["15766563"],"is_preprint":false},{"year":2016,"finding":"Barx2 is recruited to TCF/LEF binding sites at the Axin2 gene, recruits β-catenin and the co-activator GRIP-1, and induces H3K-acetylation to activate Axin2 transcription; conversely, Pax7 represses Axin2 promoter activity via HDAC1-mediated histone deacetylation.","method":"ChIP for Barx2, β-catenin, GRIP-1, and HDAC1 at Axin2 locus; promoter/intron luciferase reporter assays; myoblast overexpression/knockdown","journal":"Stem cells (Dayton, Ohio)","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP plus reporter assays defining epigenetic regulatory mechanism; single lab","pmids":["27144473"],"is_preprint":false}],"current_model":"AXIN2 is a scaffold protein and direct Wnt/β-catenin transcriptional target that functions in a negative-feedback loop: it promotes β-catenin phosphorylation and proteasomal degradation within the destruction complex (together with APC and GSK3β), acts as a nucleocytoplasmic chaperone for GSK3β to control Snail1 stability and EMT, localizes at centrosomes via C-Nap1 to regulate β-catenin phosphorylation and centrosome cohesion, is itself degraded by APC/C-CDC20 at mitotic exit to allow peak Wnt activity in G1/S, and is regulated post-translationally through its RGS-domain aggregon—which is targeted by Gαi2 and m6A demethylation—to control its polymerization/condensation state and activity."},"narrative":{"teleology":[{"year":2002,"claim":"Establishing that AXIN2 is a direct Wnt/β-catenin transcriptional target—and therefore part of a negative-feedback loop—resolved how the pathway self-limits its own output.","evidence":"TCF/LEF binding-site mutagenesis in reporter constructs, EMSA, and transgenic embryo expression analysis","pmids":["11809808","11809809"],"confidence":"High","gaps":["Quantitative relationship between Wnt signal strength and AXIN2 induction kinetics was not defined","Whether AXIN2 feedback is sufficient to fully reset β-catenin levels or requires AXIN1 cooperation was unresolved"]},{"year":2005,"claim":"Knockin rescue experiments showed that AXIN1 and AXIN2 are biochemically interchangeable, attributing their distinct loss-of-function phenotypes to expression-pattern differences rather than unique molecular activities.","evidence":"Axin2 cDNA knocked into the Axin locus in mice; viability and fertility assessed","pmids":["15899843"],"confidence":"High","gaps":["Whether the two paralogs differ in post-translational regulation (e.g., tankyrase sensitivity) was not tested","Tissue-specific quantitative expression data were limited"]},{"year":2005,"claim":"Loss of Axin2 in mice revealed its essential role in cranial suture patency, linking Wnt/β-catenin derepression to craniosynostosis through osteoprogenitor expansion.","evidence":"Axin2-null mice with craniosynostosis; β-catenin signaling and osteoblast proliferation/differentiation assays","pmids":["15790973"],"confidence":"High","gaps":["Direct target genes mediating osteoprogenitor expansion were not identified","Human craniosynostosis patients with AXIN2 mutations were not yet characterized in this study"]},{"year":2006,"claim":"Discovery of AXIN2's role as a nucleocytoplasmic chaperone for GSK3β opened a non-canonical function: by exporting GSK3β from the nucleus, AXIN2 stabilizes Snail1 to drive EMT, explaining how Wnt signaling promotes invasion.","evidence":"Knockdown/overexpression in breast cancer cells; nuclear/cytoplasmic fractionation of GSK3β; Snail1 turnover and invasion assays","pmids":["17072303"],"confidence":"High","gaps":["The nuclear export mechanism (NES-dependent vs. passive) was not dissected","Whether AXIN1 shares this GSK3β-chaperoning function was not tested"]},{"year":2009,"claim":"Genetic epistasis placed BMP2/4 and Osterix downstream of Axin2-regulated β-catenin in osteoblasts, defining a linear Axin2→β-catenin→BMP2/4→Osx pathway for bone formation.","evidence":"Axin2-null mice, β-catenin conditional deletion, BMP2/4 floxed adenoviral Cre deletion, Osx siRNA","pmids":["19737815"],"confidence":"High","gaps":["Whether this pathway operates identically in endochondral versus intramembranous ossification was not resolved","Direct transcriptional regulation of BMP2/4 by β-catenin was not shown by ChIP"]},{"year":2010,"claim":"Identification of AXIN2 at centrosomes, bound to C-Nap1, demonstrated a transcription-independent role for AXIN2-mediated β-catenin phosphorylation in centrosome cohesion.","evidence":"Reciprocal Co-IP of conductin–C-Nap1; knockdown with centrosome imaging; phospho-β-catenin mutant rescue; actinomycin D controls","pmids":["20300119"],"confidence":"High","gaps":["How centrosomal β-catenin phosphorylation physically links to centrosome linker integrity was unclear","Whether AXIN1 is also present at centrosomes was not addressed"]},{"year":2011,"claim":"Axin2 was shown to regulate oligodendrocyte progenitor differentiation and CNS remyelination, and pharmacological stabilization of Axin2 (via tankyrase inhibition) accelerated this process, establishing Axin2 as a therapeutic target in demyelinating disease.","evidence":"Axin2-KO mice and XAV939 treatment in hypoxic/demyelinating injury models","pmids":["21706018"],"confidence":"High","gaps":["Whether Axin2 acts solely through Wnt suppression or additional pathways in OLPs was not resolved","Long-term remyelination efficacy was not assessed"]},{"year":2012,"claim":"The finding that APC/C-CDC20 degrades conductin at mitotic exit explained how Wnt/β-catenin activity peaks at G1/S, coupling destruction-complex activity to cell-cycle phase.","evidence":"Cell-cycle synchronization, CDC20 knockdown, CDC20-resistant conductin mutant overexpression, colony formation assays","pmids":["22322943"],"confidence":"High","gaps":["The specific degron recognized by CDC20 in conductin was not mapped","Whether AXIN1 is similarly targeted by APC/C-CDC20 was not tested"]},{"year":2012,"claim":"Extension of the Snail1-stabilization mechanism to colorectal cancer demonstrated that AXIN2 promotes metastasis by driving EMT, revealing a pro-oncogenic facet of an otherwise tumor-suppressive gene.","evidence":"Axin2 siRNA in CRC cells; Snail1/EMT marker analysis; in vivo metastasis assays","pmids":["22745173"],"confidence":"High","gaps":["Context-dependent switch between tumor-suppressive (β-catenin degradation) and pro-oncogenic (Snail1 stabilization) functions was not mechanistically explained","Patient stratification based on AXIN2 expression for prognosis was not addressed"]},{"year":2019,"claim":"Identification of an aggregation-inhibiting sequence (aggregon) in the RGS domain of conductin/AXIN2 explained why AXIN2 is intrinsically less active than AXIN1 and provided a druggable target: peptides masking the aggregon induced polymerization and enhanced β-catenin degradation.","evidence":"Domain-swapping, aggregon point mutations, in vitro polymerization and β-catenin degradation assays, CRC growth inhibition","pmids":["31534175"],"confidence":"High","gaps":["Structural basis of aggregon-mediated polymerization inhibition at atomic resolution was not solved","In vivo pharmacokinetics and specificity of the aggregon-targeting peptide were not characterized"]},{"year":2022,"claim":"Gαi2 was identified as an endogenous activator of conductin condensation by targeting its RGS-domain aggregon, connecting G-protein signaling to Wnt pathway suppression and providing a pharmacological route (guanabenz) to enhance AXIN2 activity.","evidence":"Gαi2 co-expression/knockdown; condensate imaging; β-catenin degradation assays; CRC xenograft models; guanabenz treatment","pmids":["35115535"],"confidence":"High","gaps":["Whether other Gα subunits similarly regulate AXIN2 polymerization was not tested","The stoichiometry and dynamics of Gαi2–AXIN2 interaction in native cells were not measured"]},{"year":2023,"claim":"ALKBH5-mediated m6A demethylation of AXIN2 mRNA was shown to destabilize the transcript via loss of IGF2BP1 binding, adding an epitranscriptomic layer of AXIN2 regulation with consequences for Wnt-driven immunosuppression in colorectal cancer.","evidence":"MeRIP-seq, RNA IP, siRNA knockdown, humanized mouse models, allografts, Alkbh5 knockin mice","pmids":["37169182"],"confidence":"High","gaps":["Specific m6A sites on AXIN2 mRNA critical for IGF2BP1 binding were not individually mutated","Whether this regulatory axis operates in normal tissue homeostasis was not tested"]},{"year":2023,"claim":"Discovery of an AXIN2–ENO1 interaction in ASD neurons linked Wnt scaffold activity to glycolytic metabolism and synaptic function, suggesting AXIN2 participates in metabolic regulation beyond its canonical destruction-complex role.","evidence":"Co-IP in mouse and human ASD neurons; XAV939 treatment; glycolysis assays; behavioral rescue in Shank3−/− and VPA mice","pmids":["37078424"],"confidence":"Medium","gaps":["Directness and stoichiometry of AXIN2–ENO1 binding were not validated by a second method","Whether the metabolic effect requires intact β-catenin degradation activity of AXIN2 was not tested","Replication in independent labs is needed"]},{"year":null,"claim":"Key open questions include the structural basis of RGS-domain aggregon regulation, how AXIN2 switches between tumor-suppressive (β-catenin degradation) and pro-invasive (Snail1 stabilization) functions in different cellular contexts, and whether AXIN2's non-canonical roles at centrosomes and in metabolism are mechanistically linked.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structure of full-length AXIN2 or its condensates exists","Context-dependent switching between tumor suppression and EMT promotion is not mechanistically defined","Centrosomal, metabolic, and destruction-complex functions have not been integrated into a unified model"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,1,6,12,13]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,9,14]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,2,13]},{"term_id":"GO:0005815","term_label":"microtubule organizing center","supporting_discovery_ids":[6]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,2,13,14]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[8]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[4,5,15]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[8,13]}],"complexes":["β-catenin destruction complex"],"partners":["APC","GSK3B","CTNNB1","CNAP1","GNAI2","SNAI1","ENO1","CDC20"],"other_free_text":[]},"mechanistic_narrative":"AXIN2 (also called conductin) is a Wnt-responsive scaffold protein that operates as a core negative-feedback regulator of canonical Wnt/β-catenin signaling, with additional roles in centrosome biology, epithelial–mesenchymal transition, and cell-cycle-coupled pathway gating. Transcribed as a direct TCF/LEF target [PMID:11809808], AXIN2 assembles the β-catenin destruction complex with APC and GSK3β to drive β-catenin phosphorylation and proteasomal degradation [PMID:11809809]; its polymerization into active condensates is governed by an RGS-domain aggregon that is targeted by Gαi2 and modulated by m6A-dependent mRNA stability through ALKBH5/IGF2BP1 [PMID:31534175, PMID:35115535, PMID:37169182]. Beyond canonical destruction-complex activity, AXIN2 localizes to centrosomes via C-Nap1 to phosphorylate β-catenin independently of transcription and maintain centrosome cohesion [PMID:20300119], serves as a nucleocytoplasmic chaperone that exports GSK3β from the nucleus to stabilize Snail1 and promote EMT [PMID:17072303, PMID:22745173], and is itself degraded by APC/C-CDC20 at mitotic exit to allow peak Wnt activity at the G1/S transition [PMID:22322943]. Loss-of-function of AXIN2 in mice causes craniosynostosis through derepressed β-catenin–BMP2/4–Osx signaling in osteoprogenitors [PMID:15790973, PMID:19737815]."},"prefetch_data":{"uniprot":{"accession":"Q9Y2T1","full_name":"Axin-2","aliases":["Axin-like protein","Axil","Axis inhibition protein 2","Conductin"],"length_aa":843,"mass_kda":93.6,"function":"Inhibitor of the Wnt signaling pathway. Down-regulates beta-catenin. Probably facilitate the phosphorylation of beta-catenin and APC by GSK3B","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q9Y2T1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/AXIN2","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/AXIN2","total_profiled":1310},"omim":[{"mim_id":"617875","title":"POLYCYSTIC LIVER DISEASE 4 WITH OR WITHOUT KIDNEY CYSTS; PCLD4","url":"https://www.omim.org/entry/617875"},{"mim_id":"614940","title":"ECTODERMAL DYSPLASIA 11A, HYPOHIDROTIC/HAIR/TOOTH TYPE, AUTOSOMAL DOMINANT; ECTD11A","url":"https://www.omim.org/entry/614940"},{"mim_id":"614659","title":"APC MEMBRANE RECRUITMENT PROTEIN 2; AMER2","url":"https://www.omim.org/entry/614659"},{"mim_id":"612752","title":"CXXC FINGER PROTEIN 5; CXXC5","url":"https://www.omim.org/entry/612752"},{"mim_id":"612034","title":"APC2 REGULATOR OF WNT SIGNALING PATHWAY 2; APC2","url":"https://www.omim.org/entry/612034"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Nucleoplasm","reliability":"Uncertain"},{"location":"Plasma membrane","reliability":"Uncertain"},{"location":"Cytosol","reliability":"Uncertain"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/AXIN2"},"hgnc":{"alias_symbol":["MGC126582","DKFZp781B0869"],"prev_symbol":[]},"alphafold":{"accession":"Q9Y2T1","domains":[{"cath_id":"1.10.167.10","chopping":"75-209","consensus_level":"high","plddt":90.1457,"start":75,"end":209},{"cath_id":"2.40.240.130","chopping":"765-842","consensus_level":"high","plddt":91.3015,"start":765,"end":842}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y2T1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y2T1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y2T1-F1-predicted_aligned_error_v6.png","plddt_mean":60.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=AXIN2","jax_strain_url":"https://www.jax.org/strain/search?query=AXIN2"},"sequence":{"accession":"Q9Y2T1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9Y2T1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9Y2T1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y2T1"}},"corpus_meta":[{"pmid":"11809808","id":"PMC_11809808","title":"Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11809808","citation_count":1457,"is_preprint":false},{"pmid":"11809809","id":"PMC_11809809","title":"Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11809809","citation_count":891,"is_preprint":false},{"pmid":"26245375","id":"PMC_26245375","title":"Self-renewing diploid Axin2(+) cells fuel homeostatic renewal of the liver.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26245375","citation_count":540,"is_preprint":false},{"pmid":"17072303","id":"PMC_17072303","title":"A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells.","date":"2006","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/17072303","citation_count":538,"is_preprint":false},{"pmid":"15042511","id":"PMC_15042511","title":"Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer.","date":"2004","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15042511","citation_count":492,"is_preprint":false},{"pmid":"12101426","id":"PMC_12101426","title":"Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12101426","citation_count":398,"is_preprint":false},{"pmid":"11752446","id":"PMC_11752446","title":"Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta -catenin signaling is activated in human colon tumors.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11752446","citation_count":311,"is_preprint":false},{"pmid":"21706018","id":"PMC_21706018","title":"Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination.","date":"2011","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/21706018","citation_count":288,"is_preprint":false},{"pmid":"15790973","id":"PMC_15790973","title":"The role of Axin2 in calvarial morphogenesis and craniosynostosis.","date":"2005","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15790973","citation_count":281,"is_preprint":false},{"pmid":"30631044","id":"PMC_30631044","title":"CDX2 inhibits the proliferation and tumor formation of colon cancer cells by suppressing Wnt/β-catenin signaling via transactivation of GSK-3β and Axin2 expression.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30631044","citation_count":154,"is_preprint":false},{"pmid":"31866224","id":"PMC_31866224","title":"AXIN2+ Pericentral Hepatocytes Have Limited Contributions to Liver Homeostasis and Regeneration.","date":"2019","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/31866224","citation_count":130,"is_preprint":false},{"pmid":"37169182","id":"PMC_37169182","title":"ALKBH5 Drives Immune Suppression Via Targeting AXIN2 to Promote Colorectal Cancer and Is a Target for Boosting Immunotherapy.","date":"2023","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/37169182","citation_count":125,"is_preprint":false},{"pmid":"22745173","id":"PMC_22745173","title":"Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22745173","citation_count":125,"is_preprint":false},{"pmid":"27197202","id":"PMC_27197202","title":"c-Myb Enhances Breast Cancer Invasion and Metastasis through the Wnt/β-Catenin/Axin2 Pathway.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27197202","citation_count":117,"is_preprint":false},{"pmid":"21626677","id":"PMC_21626677","title":"Isolated oligodontia associated with mutations in EDARADD, AXIN2, MSX1, and PAX9 genes.","date":"2011","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/21626677","citation_count":117,"is_preprint":false},{"pmid":"25236910","id":"PMC_25236910","title":"AXIN1 and AXIN2 variants in gastrointestinal cancers.","date":"2014","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/25236910","citation_count":115,"is_preprint":false},{"pmid":"12711682","id":"PMC_12711682","title":"HMG box transcription factor TCF-4's interaction with CtBP1 controls the expression of the Wnt target Axin2/Conductin in human embryonic kidney cells.","date":"2003","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/12711682","citation_count":108,"is_preprint":false},{"pmid":"15899843","id":"PMC_15899843","title":"Mouse axin and axin2/conductin proteins are functionally equivalent in vivo.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15899843","citation_count":106,"is_preprint":false},{"pmid":"19737815","id":"PMC_19737815","title":"Axin2 controls bone remodeling through the beta-catenin-BMP signaling pathway in adult mice.","date":"2009","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/19737815","citation_count":98,"is_preprint":false},{"pmid":"31883834","id":"PMC_31883834","title":"Endometrial Axin2+ Cells Drive Epithelial Homeostasis, Regeneration, and Cancer following Oncogenic Transformation.","date":"2019","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/31883834","citation_count":94,"is_preprint":false},{"pmid":"23624843","id":"PMC_23624843","title":"p53 regulates nuclear GSK-3 levels through miR-34-mediated Axin2 suppression in colorectal cancer cells.","date":"2013","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/23624843","citation_count":92,"is_preprint":false},{"pmid":"17113065","id":"PMC_17113065","title":"Craniosynostosis caused by Axin2 deficiency is mediated through distinct functions of beta-catenin in proliferation and differentiation.","date":"2006","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/17113065","citation_count":91,"is_preprint":false},{"pmid":"16247484","id":"PMC_16247484","title":"Epigenetic silencing of AXIN2 in colorectal carcinoma with microsatellite instability.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16247484","citation_count":86,"is_preprint":false},{"pmid":"22322943","id":"PMC_22322943","title":"Cell cycle control of Wnt/β-catenin signalling by conductin/axin2 through CDC20.","date":"2012","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/22322943","citation_count":82,"is_preprint":false},{"pmid":"16432638","id":"PMC_16432638","title":"Axis inhibition protein 2 (AXIN2) polymorphisms may be a risk factor for selective tooth agenesis.","date":"2006","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16432638","citation_count":79,"is_preprint":false},{"pmid":"23589866","id":"PMC_23589866","title":"Lineage tracing with Axin2 reveals distinct developmental and adult populations of Wnt/β-catenin-responsive neural stem cells.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23589866","citation_count":78,"is_preprint":false},{"pmid":"33824474","id":"PMC_33824474","title":"Tumor-derived exosomal long noncoding RNA LINC01133, regulated by Periostin, contributes to pancreatic ductal adenocarcinoma epithelial-mesenchymal transition through the Wnt/β-catenin pathway by silencing AXIN2.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33824474","citation_count":70,"is_preprint":false},{"pmid":"20300119","id":"PMC_20300119","title":"Conductin/axin2 and Wnt signalling regulates centrosome cohesion.","date":"2010","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/20300119","citation_count":69,"is_preprint":false},{"pmid":"21416598","id":"PMC_21416598","title":"AXIN2-associated autosomal dominant ectodermal dysplasia and neoplastic syndrome.","date":"2011","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/21416598","citation_count":69,"is_preprint":false},{"pmid":"10049590","id":"PMC_10049590","title":"Cloning of the human homolog of conductin (AXIN2), a gene mapping to chromosome 17q23-q24.","date":"1999","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10049590","citation_count":63,"is_preprint":false},{"pmid":"29534875","id":"PMC_29534875","title":"Esculetin suppresses tumor growth and metastasis by targeting Axin2/E-cadherin axis in colorectal cancer.","date":"2018","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29534875","citation_count":57,"is_preprint":false},{"pmid":"18790474","id":"PMC_18790474","title":"Axis inhibition protein 2 (AXIN2) polymorphisms and tooth agenesis.","date":"2008","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/18790474","citation_count":55,"is_preprint":false},{"pmid":"28069701","id":"PMC_28069701","title":"Loss of Axin2 results in impaired heart valve maturation and subsequent myxomatous valve disease.","date":"2016","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/28069701","citation_count":54,"is_preprint":false},{"pmid":"25866367","id":"PMC_25866367","title":"Coordinated action of Axin1 and Axin2 suppresses β-catenin to regulate muscle stem cell function.","date":"2015","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/25866367","citation_count":51,"is_preprint":false},{"pmid":"27578179","id":"PMC_27578179","title":"Wnt/β-catenin signaling via Axin2 is required for myogenesis and, together with YAP/Taz and Tead1, active in IIa/IIx muscle fibers.","date":"2016","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/27578179","citation_count":50,"is_preprint":false},{"pmid":"21555575","id":"PMC_21555575","title":"Tissue-specific roles of Axin2 in the inhibition and activation of Wnt signaling in the mouse embryo.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21555575","citation_count":49,"is_preprint":false},{"pmid":"25380820","id":"PMC_25380820","title":"Negative-feedback regulation of the Wnt pathway by conductin/axin2 involves insensitivity to upstream signalling.","date":"2014","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/25380820","citation_count":49,"is_preprint":false},{"pmid":"28694128","id":"PMC_28694128","title":"MicroRNA-221-3p promotes pulmonary artery smooth muscle cells proliferation by targeting AXIN2 during pulmonary arterial hypertension.","date":"2017","source":"Vascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28694128","citation_count":47,"is_preprint":false},{"pmid":"17373666","id":"PMC_17373666","title":"Mutations of the Wnt antagonist AXIN2 (Conductin) result in TCF-dependent transcription in medulloblastomas.","date":"2007","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17373666","citation_count":47,"is_preprint":false},{"pmid":"30471109","id":"PMC_30471109","title":"LncRNA miR143HG suppresses bladder cancer development through inactivating Wnt/β-catenin pathway by modulating miR-1275/AXIN2 axis.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30471109","citation_count":46,"is_preprint":false},{"pmid":"18755497","id":"PMC_18755497","title":"Frameshift mutations of Wnt pathway genes AXIN2 and TCF7L2 in gastric carcinomas with high microsatellite instability.","date":"2008","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18755497","citation_count":45,"is_preprint":false},{"pmid":"34401997","id":"PMC_34401997","title":"Zeb2/Axin2-Enriched BMSC-Derived Exosomes Promote Post-Stroke Functional Recovery by Enhancing Neurogenesis and Neural Plasticity.","date":"2021","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/34401997","citation_count":44,"is_preprint":false},{"pmid":"23393221","id":"PMC_23393221","title":"Regulation of APC and AXIN2 expression by intestinal tumor suppressor CDX2 in colon cancer cells.","date":"2013","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/23393221","citation_count":43,"is_preprint":false},{"pmid":"31273221","id":"PMC_31273221","title":"miR-103/107 prolong Wnt/β-catenin signaling and colorectal cancer stemness by targeting Axin2.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31273221","citation_count":43,"is_preprint":false},{"pmid":"18372914","id":"PMC_18372914","title":"Epigenetic silencing of AXIN2/betaTrCP and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in lung tumorigenesis.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18372914","citation_count":43,"is_preprint":false},{"pmid":"23838596","id":"PMC_23838596","title":"A novel AXIN2 germline variant associated with attenuated FAP without signs of oligondontia or ectodermal dysplasia.","date":"2013","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/23838596","citation_count":43,"is_preprint":false},{"pmid":"31534175","id":"PMC_31534175","title":"An aggregon in conductin/axin2 regulates Wnt/β-catenin signaling and holds potential for cancer therapy.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31534175","citation_count":40,"is_preprint":false},{"pmid":"26191213","id":"PMC_26191213","title":"miR-107 promotes hepatocellular carcinoma cell proliferation by targeting Axin2.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26191213","citation_count":39,"is_preprint":false},{"pmid":"19623616","id":"PMC_19623616","title":"Axin2 regulates chondrocyte maturation and axial skeletal development.","date":"2010","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/19623616","citation_count":38,"is_preprint":false},{"pmid":"16820935","id":"PMC_16820935","title":"Single nucleotide polymorphism of the AXIN2 gene is preferentially associated with human lung cancer risk in a Japanese population.","date":"2006","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16820935","citation_count":38,"is_preprint":false},{"pmid":"35115535","id":"PMC_35115535","title":"Gαi2-induced conductin/axin2 condensates inhibit Wnt/β-catenin signaling and suppress cancer growth.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35115535","citation_count":37,"is_preprint":false},{"pmid":"28107521","id":"PMC_28107521","title":"Differential Roles of AXIN1 and AXIN2 in Tankyrase Inhibitor-Induced Formation of Degradasomes and β-Catenin Degradation.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28107521","citation_count":37,"is_preprint":false},{"pmid":"15538750","id":"PMC_15538750","title":"Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas.","date":"2004","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15538750","citation_count":36,"is_preprint":false},{"pmid":"16918677","id":"PMC_16918677","title":"Exclusion of coding region mutations in MSX1, PAX9 and AXIN2 in eight patients with severe oligodontia phenotype.","date":"2006","source":"Orthodontics & craniofacial research","url":"https://pubmed.ncbi.nlm.nih.gov/16918677","citation_count":36,"is_preprint":false},{"pmid":"24581859","id":"PMC_24581859","title":"Novel missense mutations in the AXIN2 gene associated with non-syndromic oligodontia.","date":"2013","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/24581859","citation_count":35,"is_preprint":false},{"pmid":"23300083","id":"PMC_23300083","title":"Runx2 protein represses Axin2 expression in osteoblasts and is required for craniosynostosis in Axin2-deficient mice.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23300083","citation_count":34,"is_preprint":false},{"pmid":"25504512","id":"PMC_25504512","title":"The roles of AXIN2 in tumorigenesis and epigenetic regulation.","date":"2015","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25504512","citation_count":33,"is_preprint":false},{"pmid":"16941501","id":"PMC_16941501","title":"Low frequency of AXIN2 mutations and high frequency of MUTYH mutations in patients with multiple polyposis.","date":"2006","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/16941501","citation_count":33,"is_preprint":false},{"pmid":"21530942","id":"PMC_21530942","title":"Sequence analysis of PAX9, MSX1 and AXIN2 genes in a Chinese oligodontia family.","date":"2011","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/21530942","citation_count":32,"is_preprint":false},{"pmid":"17013874","id":"PMC_17013874","title":"Dact1 presomitic mesoderm expression oscillates in phase with Axin2 in the somitogenesis clock of mice.","date":"2006","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/17013874","citation_count":31,"is_preprint":false},{"pmid":"11474173","id":"PMC_11474173","title":"Genomic structure, chromosome mapping and expression analysis of the human AXIN2 gene.","date":"2001","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11474173","citation_count":30,"is_preprint":false},{"pmid":"33811251","id":"PMC_33811251","title":"Evaluation of AXIN1 and AXIN2 as targets of tankyrase inhibition in hepatocellular carcinoma cell lines.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33811251","citation_count":29,"is_preprint":false},{"pmid":"28783177","id":"PMC_28783177","title":"Autophagy-dependent generation of Axin2+ cancer stem-like cells promotes hepatocarcinogenesis in liver cirrhosis.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28783177","citation_count":29,"is_preprint":false},{"pmid":"21475939","id":"PMC_21475939","title":"Strong association between lung cancer and the AXIN2 polymorphism.","date":"2009","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/21475939","citation_count":29,"is_preprint":false},{"pmid":"24166197","id":"PMC_24166197","title":"MicroRNA-205 suppresses the oral carcinoma oncogenic activity via down-regulation of Axin-2 in KB human oral cancer cell.","date":"2013","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24166197","citation_count":29,"is_preprint":false},{"pmid":"28939076","id":"PMC_28939076","title":"Snail and Axin2 expression predict the malignant transformation of oral leukoplakia.","date":"2017","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28939076","citation_count":28,"is_preprint":false},{"pmid":"33574925","id":"PMC_33574925","title":"Curcumin suppresses colorectal tumorigenesis via the Wnt/β-catenin signaling pathway by downregulating Axin2.","date":"2021","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/33574925","citation_count":28,"is_preprint":false},{"pmid":"23936395","id":"PMC_23936395","title":"Absence of endochondral ossification and craniosynostosis in posterior frontal cranial sutures of Axin2(-/-) mice.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23936395","citation_count":28,"is_preprint":false},{"pmid":"28520221","id":"PMC_28520221","title":"Rap1b Is an Effector of Axin2 Regulating Crosstalk of Signaling Pathways During Skeletal Development.","date":"2017","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/28520221","citation_count":27,"is_preprint":false},{"pmid":"28368388","id":"PMC_28368388","title":"Methylation of WNT target genes AXIN2 and DKK1 as robust biomarkers for recurrence prediction in stage II colon cancer.","date":"2017","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/28368388","citation_count":27,"is_preprint":false},{"pmid":"24964857","id":"PMC_24964857","title":"DNA methylation alterations of AXIN2 in serrated adenomas and colon carcinomas with microsatellite instability.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24964857","citation_count":26,"is_preprint":false},{"pmid":"25091576","id":"PMC_25091576","title":"The Axin2 rs2240308 polymorphism and susceptibility to lung cancer in a Chinese population.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25091576","citation_count":26,"is_preprint":false},{"pmid":"22370446","id":"PMC_22370446","title":"Association of AXIN2 with non-syndromic oral clefts in multiple populations.","date":"2012","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/22370446","citation_count":26,"is_preprint":false},{"pmid":"30279163","id":"PMC_30279163","title":"Pygo2 Regulates Adiposity and Glucose Homeostasis via β-Catenin-Axin2-GSK3β Signaling Pathway.","date":"2018","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/30279163","citation_count":25,"is_preprint":false},{"pmid":"32575385","id":"PMC_32575385","title":"GLI1 and AXIN2 Are Distinctive Markers of Human Calvarial Mesenchymal Stromal Cells in Nonsyndromic Craniosynostosis.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32575385","citation_count":25,"is_preprint":false},{"pmid":"25013500","id":"PMC_25013500","title":"Significant association between the Axin2 rs2240308 single nucleotide polymorphism and the incidence of prostate cancer.","date":"2014","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/25013500","citation_count":24,"is_preprint":false},{"pmid":"27144473","id":"PMC_27144473","title":"Barx2 and Pax7 Regulate Axin2 Expression in Myoblasts by Interaction with β-Catenin and Chromatin Remodelling.","date":"2016","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/27144473","citation_count":24,"is_preprint":false},{"pmid":"27701636","id":"PMC_27701636","title":"Loss of Axin2 Causes Ocular Defects During Mouse Eye Development.","date":"2016","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/27701636","citation_count":23,"is_preprint":false},{"pmid":"30671715","id":"PMC_30671715","title":"Phenotypic confirmation of oligodontia, colorectal polyposis and cancer in a family carrying an exon 7 nonsense variant in the AXIN2 gene.","date":"2019","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30671715","citation_count":23,"is_preprint":false},{"pmid":"36155281","id":"PMC_36155281","title":"Hederagenin ameliorates cisplatin-induced acute kidney injury via inhibiting long non-coding RNA A330074k22Rik/Axin2/β-catenin signalling pathway.","date":"2022","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36155281","citation_count":22,"is_preprint":false},{"pmid":"30070321","id":"PMC_30070321","title":"MiR-183 maintains canonical Wnt signaling activity and regulates growth and apoptosis in bladder cancer via targeting AXIN2.","date":"2018","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30070321","citation_count":22,"is_preprint":false},{"pmid":"37488774","id":"PMC_37488774","title":"Pancreatic stellate cell-derived exosomal tRF-19-PNR8YPJZ promotes proliferation and mobility of pancreatic cancer through AXIN2.","date":"2023","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37488774","citation_count":21,"is_preprint":false},{"pmid":"29307822","id":"PMC_29307822","title":"miR-3120-5p promotes colon cancer stem cell stemness and invasiveness through targeting Axin2.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29307822","citation_count":21,"is_preprint":false},{"pmid":"26406231","id":"PMC_26406231","title":"A Novel AXIN2 Missense Mutation Is Associated with Non-Syndromic Oligodontia.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26406231","citation_count":21,"is_preprint":false},{"pmid":"35197279","id":"PMC_35197279","title":"The nonredundant nature of the Axin2 regulatory network in the canonical Wnt signaling pathway.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35197279","citation_count":21,"is_preprint":false},{"pmid":"28759178","id":"PMC_28759178","title":"Mutations in AXIN2 gene as a risk factor for tooth agenesis and cancer: A review.","date":"2017","source":"Neuro endocrinology letters","url":"https://pubmed.ncbi.nlm.nih.gov/28759178","citation_count":20,"is_preprint":false},{"pmid":"27090353","id":"PMC_27090353","title":"Functional analysis of a novel missense mutation in AXIN2 associated with non-syndromic tooth agenesis.","date":"2016","source":"European journal of oral sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27090353","citation_count":20,"is_preprint":false},{"pmid":"26617789","id":"PMC_26617789","title":"MiR-374a promotes the proliferation of osteosarcoma cell proliferation by targeting Axin2.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26617789","citation_count":19,"is_preprint":false},{"pmid":"36331809","id":"PMC_36331809","title":"LncRNA GAS5 regulates the Wnt/β-catenin pathway through the miR-18a-5p/AXIN2/GSK3β axis to inhibit the proliferation and migration of bladder cancer cells.","date":"2022","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/36331809","citation_count":18,"is_preprint":false},{"pmid":"34093820","id":"PMC_34093820","title":"MicroRNA-1246 by Targeting AXIN2 and GSK-3β Overcomes Drug Resistance and Induces Apoptosis in Chemo-resistant Leukemia Cells.","date":"2021","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34093820","citation_count":18,"is_preprint":false},{"pmid":"21733995","id":"PMC_21733995","title":"Identification of genetic alterations of AXIN2 gene in adrenocortical tumors.","date":"2011","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/21733995","citation_count":18,"is_preprint":false},{"pmid":"37054704","id":"PMC_37054704","title":"Stem cell competition driven by the Axin2-p53 axis controls brain size during murine development.","date":"2023","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/37054704","citation_count":17,"is_preprint":false},{"pmid":"37078424","id":"PMC_37078424","title":"Axin2 coupled excessive Wnt-glycolysis signaling mediates social defect in autism spectrum disorders.","date":"2023","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37078424","citation_count":17,"is_preprint":false},{"pmid":"26252180","id":"PMC_26252180","title":"MicroRNA-374a promotes esophageal cancer cell proliferation via Axin2 suppression.","date":"2015","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/26252180","citation_count":17,"is_preprint":false},{"pmid":"34817745","id":"PMC_34817745","title":"Rare germline variants in the AXIN2 gene in families with colonic polyposis and colorectal cancer.","date":"2021","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34817745","citation_count":16,"is_preprint":false},{"pmid":"24222224","id":"PMC_24222224","title":"Mutational analysis of AXIN2, MSX1, and PAX9 in two Mexican oligodontia families.","date":"2013","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/24222224","citation_count":16,"is_preprint":false},{"pmid":"33046030","id":"PMC_33046030","title":"The Axin2-snail axis promotes bone invasion by activating cancer-associated fibroblasts in oral squamous cell carcinoma.","date":"2020","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33046030","citation_count":16,"is_preprint":false},{"pmid":"15766563","id":"PMC_15766563","title":"E2F1 up-regulates the expression of the tumour suppressor axin2 both by activation of transcription and by mRNA stabilisation.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15766563","citation_count":16,"is_preprint":false},{"pmid":"32643876","id":"PMC_32643876","title":"A novel Axin2 knock-in mouse model for visualization and lineage tracing of WNT/CTNNB1 responsive cells.","date":"2020","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/32643876","citation_count":15,"is_preprint":false},{"pmid":"28378643","id":"PMC_28378643","title":"Association study between genetic variations in Axin2 gene and lung cancer risk in North Indian population: A multiple interaction analysis.","date":"2017","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28378643","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49515,"output_tokens":5931,"usd":0.118755},"stage2":{"model":"claude-opus-4-6","input_tokens":9794,"output_tokens":3679,"usd":0.211418},"total_usd":0.330173,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"AXIN2 is a direct transcriptional target of the Wnt/β-catenin pathway, induced through TCF/LEF binding sites in its promoter and first intron; mutation or deletion of these sites abolished β-catenin-mediated induction, establishing a negative feedback loop where AXIN2 promotes β-catenin phosphorylation and degradation.\",\n      \"method\": \"Reporter constructs with promoter/intron fragments, EMSA with Tcf/LEF sites, transgenic embryo expression, endogenous mRNA/protein induction assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (EMSA, reporter assays, mutagenesis, transgenic mice) in two independent papers\",\n      \"pmids\": [\"11809808\", \"11809809\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"AXIN2/conductin functions as a negative regulator of Wnt signaling by inducing β-catenin degradation through functional interaction with the tumor suppressor APC and the serine/threonine kinase GSK3β.\",\n      \"method\": \"Co-functional studies in tumor cell lines with dominant-negative TCF, Wnt-1 and Dishevelled activation, western blot for β-catenin\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — replicated across multiple studies, consistent with established destruction complex mechanism\",\n      \"pmids\": [\"11809809\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Canonical Wnt signaling stabilizes the Snail1 zinc-finger transcription factor through an Axin2-GSK3β axis: Axin2 acts as a nucleocytoplasmic chaperone for GSK3β, relocating it from the nucleus, thereby reducing GSK3β-mediated Snail1 phosphorylation and degradation to drive EMT and breast cancer invasion.\",\n      \"method\": \"Knockdown/overexpression in breast cancer cells, nuclear/cytoplasmic fractionation, Snail1 protein turnover assays, invasion assays\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple mechanistic readouts (GSK3β localization, Snail1 stability, invasion) in a single high-impact study\",\n      \"pmids\": [\"17072303\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Axin and Axin2 proteins are functionally equivalent in vivo; knockin of Axin2 cDNA under the Axin locus rescues Axin-null lethality, demonstrating that their different phenotypes arise from distinct expression patterns rather than different biochemical activities.\",\n      \"method\": \"Knockin mouse generation (Axin locus replaced with Axin or Axin2 cDNA), viability and fertility assessment of homozygotes\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vivo genetic equivalence demonstrated by knockin rescue\",\n      \"pmids\": [\"15899843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Axin2 is expressed at osteogenic fronts and periosteum of developing sutures; targeted disruption of Axin2 causes craniosynostosis through enhanced β-catenin signaling, promoting osteoprogenitor expansion and accelerated osteoblast differentiation.\",\n      \"method\": \"Axin2-null mouse analysis, in vivo/in vitro osteoblast proliferation and differentiation assays, β-catenin signaling readouts\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with defined cellular phenotype and pathway placement\",\n      \"pmids\": [\"15790973\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In osteoprogenitors, β-catenin acts as a transcriptional co-activator driving cyclin D1 expression to promote proliferation; upon differentiation, β-catenin switches to an adhesion role via adherens junctions. Haploid deficiency of β-catenin rescues Axin2-null craniosynostosis, confirming that Axin2 suppresses both proliferative and adhesive β-catenin functions.\",\n      \"method\": \"Genetic rescue (Axin2-null × β-catenin heterozygous mice), BMP signaling assays, adherens junction analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis demonstrated by double-mutant rescue with defined phenotypic readout\",\n      \"pmids\": [\"17113065\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Conductin/Axin2 localizes at centrosomes by binding to the centriole-associated protein C-Nap1, and promotes phosphorylation of β-catenin (Ser33/37, Thr41) at centrosomes; loss of conductin causes premature centrosome separation dependent on β-catenin but independent of β-catenin-mediated transcription.\",\n      \"method\": \"Co-immunoprecipitation (conductin–C-Nap1), knockdown/knockout, centrosome imaging, phospho-β-catenin mutant rescue, transcription inhibitor controls\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal binding demonstrated, phenotype rescued by phospho-mimetic mutant, transcription-independent mechanism confirmed\",\n      \"pmids\": [\"20300119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Axin2 is required for normal kinetics of oligodendrocyte progenitor differentiation and remyelination; tankyrase inhibitor XAV939 stabilizes Axin2 levels in OLPs and accelerates their differentiation after hypoxic/demyelinating injury.\",\n      \"method\": \"Axin2 KO mice, XAV939 pharmacological stabilization, remyelination assays in brain and spinal cord injury models\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mice with defined cellular phenotype plus pharmacological rescue with mechanism\",\n      \"pmids\": [\"21706018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Conductin/Axin2 levels peak at G2/M and are degraded by the APC/C cofactor CDC20, allowing maximal Wnt/β-catenin target gene activity at G1/S; CDC20-resistant conductin inhibits Wnt signaling and colony formation of colorectal cancer cells.\",\n      \"method\": \"Cell cycle synchronization, CDC20 knockdown, CDC20-resistant conductin overexpression, colony formation assays, β-catenin phosphorylation analysis\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CDC20 identified as the E3 adaptor for conductin degradation with functional consequence on Wnt signaling\",\n      \"pmids\": [\"22322943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"In colorectal cancer cells with activated Wnt signaling, Axin2 promotes oncogenic behavior by stabilizing Snail1 activity and driving EMT; silencing Axin2 decreases Snail1, reverses EMT, and inhibits invasion and metastasis.\",\n      \"method\": \"Axin2 siRNA knockdown in CRC cells, Snail1 activity assays, EMT markers, in vivo metastasis models, transcriptome analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in vitro and in vivo, mechanistic pathway defined\",\n      \"pmids\": [\"22745173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"p53 regulates nuclear GSK3β levels via miR-34-mediated suppression of Axin2; Axin2 acts as a cytoplasmic anchor retaining GSK3β outside the nucleus, and its suppression increases nuclear GSK3β abundance, leading to decreased Snail expression.\",\n      \"method\": \"miR-34a overexpression, Axin2 UTR-reporter assays, nuclear/cytoplasmic GSK3β fractionation, Snail protein level measurement, miR-sponge construct\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — single lab, mechanistic chain established through UTR reporter and fractionation but limited by single-method validation of each step\",\n      \"pmids\": [\"23624843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Conductin/Axin2 shows reduced binding to Dvl2 compared to Axin1, making β-catenin degradation by conductin relatively insensitive to Dvl-mediated inhibition; this insensitivity to upstream Wnt pathway components is a key feature of conductin's role as a negative-feedback regulator.\",\n      \"method\": \"Domain-swap constructs, Co-IP of conductin/axin with Dvl2, β-catenin degradation assays with Dvl2 co-expression\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP and functional assays in single lab establishing biochemical mechanism\",\n      \"pmids\": [\"25380820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"AXIN2 is the rate-limiting scaffold for formation of tankyrase-inhibitor-induced degradasomes (β-catenin destruction complex assemblies); depletion of AXIN2 (but not AXIN1) substantially impairs degradasome formation and β-catenin degradation in colorectal cancer cells.\",\n      \"method\": \"siRNA knockdown of AXIN1 vs AXIN2 in SW480 cells treated with tankyrase inhibitor G007-LK, immunofluorescence of degradasomes, β-catenin levels\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic dissection of AXIN1 vs AXIN2 roles with defined phenotypic readout\",\n      \"pmids\": [\"28107521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Conductin/Axin2 contains an aggregation site (aggregon) in its RGS domain that prevents its polymerization and limits its activity; mutations masking this aggregon enhance conductin polymerization and β-catenin degradation. A peptide targeting this aggregon induces conductin polymerization, enhancing β-catenin degradation and suppressing colorectal cancer growth.\",\n      \"method\": \"Domain-swapping between axin and conductin, point mutations of aggregon, in vitro polymerization assays, β-catenin degradation assays, colorectal cancer cell growth assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — biochemical reconstitution of polymerization, mutagenesis validation, functional cancer cell assays\",\n      \"pmids\": [\"31534175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Gαi2, a subunit of trimeric G-proteins, induces conductin/Axin2 condensation by targeting the polymerization-inhibiting aggregon in its RGS domain, promoting conductin-mediated β-catenin degradation and Wnt pathway suppression; the FDA-approved drug guanabenz activates Gαi2 to inhibit Wnt signaling via conductin condensation.\",\n      \"method\": \"Gαi2 co-expression/knockdown, condensate imaging, β-catenin degradation assays, colorectal cancer xenograft models, guanabenz treatment\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway (Gαi2→aggregon→condensation→β-catenin degradation) validated with multiple orthogonal methods in vitro and in vivo\",\n      \"pmids\": [\"35115535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Axin2 regulates bone remodeling by controlling β-catenin-BMP2/4-Osx signaling in osteoblasts; Axin2 KO mice show increased trabecular bone mass and osteoblast differentiation, with elevated BMP2/4 expression and phospho-Smad1/5, and BMP2/4 deletion blocks β-catenin-induced osteoblast marker expression.\",\n      \"method\": \"Axin2-null mice, BMS cell isolation, β-catenin conditional deletion, BIO chemical inhibitor, Bmp2/4-flox adenoviral Cre deletion, siRNA knockdown of Osx\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic epistasis experiments establishing Axin2→β-catenin→BMP2/4→Osx pathway\",\n      \"pmids\": [\"19737815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Runx2 represses Axin2 transcription through binding to multiple Axin2 promoter regions in a manner dependent on Hdac3; haploinsufficiency of Runx2 in Axin2-null mice rescues craniosynostosis, placing Runx2-Hdac3 upstream of Axin2 in intramembranous bone development.\",\n      \"method\": \"ChIP (Runx2 at Axin2 promoter), Hdac3 co-repressor assay, Axin2-null × Runx2-heterozygous double mutant mouse rescue\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus double-mutant genetic rescue defining transcriptional regulatory pathway\",\n      \"pmids\": [\"23300083\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TCF-4 interacts with the transcriptional co-repressor CtBP1 via its C-terminus; CtBP1 represses TCF/β-catenin-dependent transcription including endogenous Axin2/conductin expression, and this repression is relieved by histone deacetylase inhibition (trichostatin A), indicating HDAC-dependent co-repressor activity.\",\n      \"method\": \"Co-IP of TCF-4 and CtBP1, synthetic promoter reporter assay, endogenous Axin2 mRNA measurement, trichostatin A treatment\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — Co-IP plus reporter assay in single study, mechanism partially defined\",\n      \"pmids\": [\"12711682\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In Axin2(canp) mutant mice carrying a V26D substitution in an N-terminal motif, Axin2 protein is more stable than wild type, leading to decreased Wnt signaling in most tissues but paradoxical increased Wnt activity in the late primitive streak; tankyrase inhibitor-induced Axin stabilization in wild-type embryos recapitulates this tissue-specific paradox.\",\n      \"method\": \"ENU-induced V26D knockin mice, Wnt reporter readouts in different tissues, tankyrase inhibitor treatment of wild-type embryos\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis and pharmacological validation, tissue-specific mechanistic insight from single lab\",\n      \"pmids\": [\"21555575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Rap1b acts downstream of Axin2 in skeletal progenitor cells; Axin2 regulates Rap1b through modulation of canonical BMP signaling, and Rap1b-mediated inhibition of MAPK antagonizes FGF signaling to repress osteoblast differentiation while promoting chondrogenesis.\",\n      \"method\": \"Axin2 and Rap1b knockout mice, genetic epistasis, BMP/FGF/MAPK signaling assays, cell fate analysis\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic pathway placement with multiple signaling readouts; single lab\",\n      \"pmids\": [\"28520221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Axin2 suppresses p53 signaling at the post-transcriptional level to maintain neural progenitor cell fitness; in genetic mosaic conditions, Axin2-deficient cells are eliminated by p53-dependent apoptosis (cell competition), and combined Axin2/p53 loss increases cortical area and thickness.\",\n      \"method\": \"Mosaic Axin2 knockout vs. homogeneous knockout mice, genetic double mutant (Axin2 + Trp53), cortical area/thickness measurement, apoptosis assays\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis via double knockout with defined developmental phenotype; single lab\",\n      \"pmids\": [\"37054704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ALKBH5, an m6A RNA eraser, binds and demethylates AXIN2 mRNA, causing its dissociation from the m6A reader IGF2BP1 and consequent degradation, thereby hyperactivating Wnt/β-catenin signaling and inducing DKK1-mediated immunosuppression in colorectal cancer.\",\n      \"method\": \"MeRIP-seq, RNA IP, siRNA knockdown, humanized mouse models, allografts, Alkbh5 knockin mice\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — m6A modification site on AXIN2 mRNA identified by MeRIP-seq, mechanism validated in multiple in vivo models\",\n      \"pmids\": [\"37169182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In ASD neurons, Axin2 interacts with the glycolytic enzyme ENO1; the tankyrase inhibitor XAV939 blocks Axin2/ENO1 interaction and stabilizes Axin2, shifting the glycolysis/oxidative phosphorylation balance and rescuing synaptic maturation and social behavior deficits.\",\n      \"method\": \"Co-IP of Axin2 and ENO1 in ASD mouse/human neurons, XAV939 treatment, glycolysis assays, behavioral rescue in Shank3-/- and VPA-treated mice\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — novel Axin2–ENO1 interaction identified by Co-IP with functional rescue; single lab\",\n      \"pmids\": [\"37078424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"E2F1 upregulates Axin2 by two independent mechanisms: direct transcriptional activation of a specific 5' UTR variant via canonical E2F binding sites, and stabilization of Axin2 mRNA, establishing Axin2 as a point of cross-talk between the Rb/E2F and Wnt/β-catenin pathways.\",\n      \"method\": \"Reporter assays with E2F binding site mutations, mRNA stability assays, E2F1 overexpression\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — two mechanisms identified but single lab with partial validation\",\n      \"pmids\": [\"15766563\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Barx2 is recruited to TCF/LEF binding sites at the Axin2 gene, recruits β-catenin and the co-activator GRIP-1, and induces H3K-acetylation to activate Axin2 transcription; conversely, Pax7 represses Axin2 promoter activity via HDAC1-mediated histone deacetylation.\",\n      \"method\": \"ChIP for Barx2, β-catenin, GRIP-1, and HDAC1 at Axin2 locus; promoter/intron luciferase reporter assays; myoblast overexpression/knockdown\",\n      \"journal\": \"Stem cells (Dayton, Ohio)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus reporter assays defining epigenetic regulatory mechanism; single lab\",\n      \"pmids\": [\"27144473\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"AXIN2 is a scaffold protein and direct Wnt/β-catenin transcriptional target that functions in a negative-feedback loop: it promotes β-catenin phosphorylation and proteasomal degradation within the destruction complex (together with APC and GSK3β), acts as a nucleocytoplasmic chaperone for GSK3β to control Snail1 stability and EMT, localizes at centrosomes via C-Nap1 to regulate β-catenin phosphorylation and centrosome cohesion, is itself degraded by APC/C-CDC20 at mitotic exit to allow peak Wnt activity in G1/S, and is regulated post-translationally through its RGS-domain aggregon—which is targeted by Gαi2 and m6A demethylation—to control its polymerization/condensation state and activity.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"AXIN2 (also called conductin) is a Wnt-responsive scaffold protein that operates as a core negative-feedback regulator of canonical Wnt/β-catenin signaling, with additional roles in centrosome biology, epithelial–mesenchymal transition, and cell-cycle-coupled pathway gating. Transcribed as a direct TCF/LEF target [PMID:11809808], AXIN2 assembles the β-catenin destruction complex with APC and GSK3β to drive β-catenin phosphorylation and proteasomal degradation [PMID:11809809]; its polymerization into active condensates is governed by an RGS-domain aggregon that is targeted by Gαi2 and modulated by m6A-dependent mRNA stability through ALKBH5/IGF2BP1 [PMID:31534175, PMID:35115535, PMID:37169182]. Beyond canonical destruction-complex activity, AXIN2 localizes to centrosomes via C-Nap1 to phosphorylate β-catenin independently of transcription and maintain centrosome cohesion [PMID:20300119], serves as a nucleocytoplasmic chaperone that exports GSK3β from the nucleus to stabilize Snail1 and promote EMT [PMID:17072303, PMID:22745173], and is itself degraded by APC/C-CDC20 at mitotic exit to allow peak Wnt activity at the G1/S transition [PMID:22322943]. Loss-of-function of AXIN2 in mice causes craniosynostosis through derepressed β-catenin–BMP2/4–Osx signaling in osteoprogenitors [PMID:15790973, PMID:19737815].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Establishing that AXIN2 is a direct Wnt/β-catenin transcriptional target—and therefore part of a negative-feedback loop—resolved how the pathway self-limits its own output.\",\n      \"evidence\": \"TCF/LEF binding-site mutagenesis in reporter constructs, EMSA, and transgenic embryo expression analysis\",\n      \"pmids\": [\"11809808\", \"11809809\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Quantitative relationship between Wnt signal strength and AXIN2 induction kinetics was not defined\",\n        \"Whether AXIN2 feedback is sufficient to fully reset β-catenin levels or requires AXIN1 cooperation was unresolved\"\n      ]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Knockin rescue experiments showed that AXIN1 and AXIN2 are biochemically interchangeable, attributing their distinct loss-of-function phenotypes to expression-pattern differences rather than unique molecular activities.\",\n      \"evidence\": \"Axin2 cDNA knocked into the Axin locus in mice; viability and fertility assessed\",\n      \"pmids\": [\"15899843\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether the two paralogs differ in post-translational regulation (e.g., tankyrase sensitivity) was not tested\",\n        \"Tissue-specific quantitative expression data were limited\"\n      ]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Loss of Axin2 in mice revealed its essential role in cranial suture patency, linking Wnt/β-catenin derepression to craniosynostosis through osteoprogenitor expansion.\",\n      \"evidence\": \"Axin2-null mice with craniosynostosis; β-catenin signaling and osteoblast proliferation/differentiation assays\",\n      \"pmids\": [\"15790973\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct target genes mediating osteoprogenitor expansion were not identified\",\n        \"Human craniosynostosis patients with AXIN2 mutations were not yet characterized in this study\"\n      ]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Discovery of AXIN2's role as a nucleocytoplasmic chaperone for GSK3β opened a non-canonical function: by exporting GSK3β from the nucleus, AXIN2 stabilizes Snail1 to drive EMT, explaining how Wnt signaling promotes invasion.\",\n      \"evidence\": \"Knockdown/overexpression in breast cancer cells; nuclear/cytoplasmic fractionation of GSK3β; Snail1 turnover and invasion assays\",\n      \"pmids\": [\"17072303\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The nuclear export mechanism (NES-dependent vs. passive) was not dissected\",\n        \"Whether AXIN1 shares this GSK3β-chaperoning function was not tested\"\n      ]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Genetic epistasis placed BMP2/4 and Osterix downstream of Axin2-regulated β-catenin in osteoblasts, defining a linear Axin2→β-catenin→BMP2/4→Osx pathway for bone formation.\",\n      \"evidence\": \"Axin2-null mice, β-catenin conditional deletion, BMP2/4 floxed adenoviral Cre deletion, Osx siRNA\",\n      \"pmids\": [\"19737815\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether this pathway operates identically in endochondral versus intramembranous ossification was not resolved\",\n        \"Direct transcriptional regulation of BMP2/4 by β-catenin was not shown by ChIP\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identification of AXIN2 at centrosomes, bound to C-Nap1, demonstrated a transcription-independent role for AXIN2-mediated β-catenin phosphorylation in centrosome cohesion.\",\n      \"evidence\": \"Reciprocal Co-IP of conductin–C-Nap1; knockdown with centrosome imaging; phospho-β-catenin mutant rescue; actinomycin D controls\",\n      \"pmids\": [\"20300119\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"How centrosomal β-catenin phosphorylation physically links to centrosome linker integrity was unclear\",\n        \"Whether AXIN1 is also present at centrosomes was not addressed\"\n      ]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Axin2 was shown to regulate oligodendrocyte progenitor differentiation and CNS remyelination, and pharmacological stabilization of Axin2 (via tankyrase inhibition) accelerated this process, establishing Axin2 as a therapeutic target in demyelinating disease.\",\n      \"evidence\": \"Axin2-KO mice and XAV939 treatment in hypoxic/demyelinating injury models\",\n      \"pmids\": [\"21706018\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether Axin2 acts solely through Wnt suppression or additional pathways in OLPs was not resolved\",\n        \"Long-term remyelination efficacy was not assessed\"\n      ]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"The finding that APC/C-CDC20 degrades conductin at mitotic exit explained how Wnt/β-catenin activity peaks at G1/S, coupling destruction-complex activity to cell-cycle phase.\",\n      \"evidence\": \"Cell-cycle synchronization, CDC20 knockdown, CDC20-resistant conductin mutant overexpression, colony formation assays\",\n      \"pmids\": [\"22322943\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The specific degron recognized by CDC20 in conductin was not mapped\",\n        \"Whether AXIN1 is similarly targeted by APC/C-CDC20 was not tested\"\n      ]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Extension of the Snail1-stabilization mechanism to colorectal cancer demonstrated that AXIN2 promotes metastasis by driving EMT, revealing a pro-oncogenic facet of an otherwise tumor-suppressive gene.\",\n      \"evidence\": \"Axin2 siRNA in CRC cells; Snail1/EMT marker analysis; in vivo metastasis assays\",\n      \"pmids\": [\"22745173\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Context-dependent switch between tumor-suppressive (β-catenin degradation) and pro-oncogenic (Snail1 stabilization) functions was not mechanistically explained\",\n        \"Patient stratification based on AXIN2 expression for prognosis was not addressed\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identification of an aggregation-inhibiting sequence (aggregon) in the RGS domain of conductin/AXIN2 explained why AXIN2 is intrinsically less active than AXIN1 and provided a druggable target: peptides masking the aggregon induced polymerization and enhanced β-catenin degradation.\",\n      \"evidence\": \"Domain-swapping, aggregon point mutations, in vitro polymerization and β-catenin degradation assays, CRC growth inhibition\",\n      \"pmids\": [\"31534175\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of aggregon-mediated polymerization inhibition at atomic resolution was not solved\",\n        \"In vivo pharmacokinetics and specificity of the aggregon-targeting peptide were not characterized\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Gαi2 was identified as an endogenous activator of conductin condensation by targeting its RGS-domain aggregon, connecting G-protein signaling to Wnt pathway suppression and providing a pharmacological route (guanabenz) to enhance AXIN2 activity.\",\n      \"evidence\": \"Gαi2 co-expression/knockdown; condensate imaging; β-catenin degradation assays; CRC xenograft models; guanabenz treatment\",\n      \"pmids\": [\"35115535\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether other Gα subunits similarly regulate AXIN2 polymerization was not tested\",\n        \"The stoichiometry and dynamics of Gαi2–AXIN2 interaction in native cells were not measured\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"ALKBH5-mediated m6A demethylation of AXIN2 mRNA was shown to destabilize the transcript via loss of IGF2BP1 binding, adding an epitranscriptomic layer of AXIN2 regulation with consequences for Wnt-driven immunosuppression in colorectal cancer.\",\n      \"evidence\": \"MeRIP-seq, RNA IP, siRNA knockdown, humanized mouse models, allografts, Alkbh5 knockin mice\",\n      \"pmids\": [\"37169182\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Specific m6A sites on AXIN2 mRNA critical for IGF2BP1 binding were not individually mutated\",\n        \"Whether this regulatory axis operates in normal tissue homeostasis was not tested\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Discovery of an AXIN2–ENO1 interaction in ASD neurons linked Wnt scaffold activity to glycolytic metabolism and synaptic function, suggesting AXIN2 participates in metabolic regulation beyond its canonical destruction-complex role.\",\n      \"evidence\": \"Co-IP in mouse and human ASD neurons; XAV939 treatment; glycolysis assays; behavioral rescue in Shank3−/− and VPA mice\",\n      \"pmids\": [\"37078424\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Directness and stoichiometry of AXIN2–ENO1 binding were not validated by a second method\",\n        \"Whether the metabolic effect requires intact β-catenin degradation activity of AXIN2 was not tested\",\n        \"Replication in independent labs is needed\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include the structural basis of RGS-domain aggregon regulation, how AXIN2 switches between tumor-suppressive (β-catenin degradation) and pro-invasive (Snail1 stabilization) functions in different cellular contexts, and whether AXIN2's non-canonical roles at centrosomes and in metabolism are mechanistically linked.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No high-resolution structure of full-length AXIN2 or its condensates exists\",\n        \"Context-dependent switching between tumor suppression and EMT promotion is not mechanistically defined\",\n        \"Centrosomal, metabolic, and destruction-complex functions have not been integrated into a unified model\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 1, 6, 12, 13]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 9, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 2, 13]},\n      {\"term_id\": \"GO:0005815\", \"supporting_discovery_ids\": [6]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 13, 14]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [8]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 5, 15]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [8, 13]}\n    ],\n    \"complexes\": [\n      \"β-catenin destruction complex\"\n    ],\n    \"partners\": [\n      \"APC\",\n      \"GSK3B\",\n      \"CTNNB1\",\n      \"CNAP1\",\n      \"GNAI2\",\n      \"SNAI1\",\n      \"ENO1\",\n      \"CDC20\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}